Trial Profile
CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs Buprenorphine/naloxone (Primary) ; Naltrexone (Primary)
- Indications Opioid-related disorders
- Focus Therapeutic Use
- Acronyms X:BOT
- 01 Jul 2022 Results published in the Drug and Alcohol Dependence
- 18 Apr 2022 Results published in the Journal of Clinical Psychiatry
- 01 Mar 2022 Results published in the Addiction Biology